Association of NQO1 rs1800566 polymorphism and the risk of colorectal cancer: a meta-analysis

IntroductionNAD(P)H:quinone oxidoreductase 1 (NQO1) rs1800566 polymorphism is found to have a lower enzymatic activity, which may result in increased incidence of several kinds of carcinomas including colorectal cancer. Results from published studies on the association of NQO1 rs1800566 genetic polymorphism with the risk of colorectal cancer are inconsistent. We performed a meta-analysis to summarize the possible association.Materials and methodsAll eligible published studies were searched from PubMed and Elsevier ScienceDirect. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were analyzed for additive, dominant, and recessive models to assess the association using fixed- or random-effect model.ResultsWe identified 12 case-control studies that include 5,525 cases and 6,272 controls for the present meta-analysis. Significant associations between NQO1 rs1800566 genetic polymorphism and risk of colorectal cancer were observed in additive (OR = 1.09, 95% CI = 1.02–1.16, p = 0.009) and dominant models (OR = 1.12, 95% CI = 1.04–1.21, p = 0.004 for TT + CT vs. CC). Moreover, in the subgroup analysis based on ethnicity, significant associations were observed in Caucasians but not in Asians.ConclusionsThis meta-analysis provided evidence that NQO1 rs1800566 genetic polymorphism was associated with increased risk of colorectal cancer and that the T allele probably acts as an important risk factor.

[1]  Nikolaos A Patsopoulos,et al.  Uncertainty in heterogeneity estimates in meta-analyses , 2007, BMJ : British Medical Journal.

[2]  P. O'Brien.  Molecular mechanisms of quinone cytotoxicity. , 1991, Chemico-biological interactions.

[3]  A. Begleiter,et al.  Induction of DT-diaphorase in cancer chemoprevention and chemotherapy. , 1997, Oncology research.

[4]  A. Begleiter,et al.  Induction of NAD(P)H quinone: oxidoreductase1 inhibits carcinogen-induced aberrant crypt foci in colons of Sprague-Dawley rats. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[5]  A. Begleiter,et al.  Effect of post-initiation induction of NQO1 by oltipraz on AOM induced colon tumor formation in Sprague-Dawley rats , 2005 .

[6]  A. Naccarati,et al.  Association between exposure-relevant polymorphisms in CYP1B1, EPHX1, NQO1, GSTM1, GSTP1 and GSTT1 and risk of colorectal cancer in a Czech population. , 2010, Oncology reports.

[7]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[8]  A. Chapelle,et al.  Genetic predisposition to colorectal cancer , 2004, Nature Reviews Cancer.

[9]  Nilanjan Chatterjee,et al.  CYP1A1 Val462 and NQO1 Ser187 polymorphisms, cigarette use, and risk for colorectal adenoma. , 2005, Carcinogenesis.

[10]  J. Barrett,et al.  Polymorphisms in xenobiotic metabolizing enzymes and diet influence colorectal adenoma risk , 2010, Pharmacogenetics and genomics.

[11]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[12]  M. Spitz,et al.  Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. , 1997, British Journal of Cancer.

[13]  Zuo-Feng Zhang,et al.  NAD(P)H:Quinone Oxidoreductase 1 (NQO1) Pro187Ser Polymorphism and the Risk of Lung, Bladder, and Colorectal Cancers: a Meta-analysis , 2006, Cancer Epidemiology Biomarkers & Prevention.

[14]  G. Doherty,et al.  Factors influencing the induction of DT-diaphorase activity by 1,2-dithiole-3-thione in human tumor cell lines. , 2001, Biochemical pharmacology.

[15]  D. Ross,et al.  DT-diaphorase in activation and detoxification of quinones , 1993, Cancer and Metastasis Reviews.

[16]  P. Workman,et al.  Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. , 1994, Oncology research.

[17]  G M Cohen,et al.  Quinone chemistry and toxicity. , 1992, Toxicology and applied pharmacology.

[18]  J. Barrett,et al.  A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. , 2002, Carcinogenesis.

[19]  J. Wiencke,et al.  NAD(P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors. , 2000, Carcinogenesis.

[20]  S. Chen,et al.  Structure-function studies of DT-diaphorase (NQO1) and NRH: quinone oxidoreductase (NQO2). , 2000, Free radical biology & medicine.

[21]  K. Danenberg,et al.  NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. , 1992, Cancer research.

[22]  W. Laan,et al.  NQO1 and NFE2L2 polymorphisms, fruit and vegetable intake and smoking and the risk of colorectal adenomas in an endoscopy‐based population , 2007, International journal of cancer.

[23]  M. Ranson,et al.  DT-diaphorase: a target for new anticancer drugs. , 2004, Cancer treatment reviews.

[24]  A. Sameer,et al.  NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and colorectal cancer predisposition in the ethnic Kashmiri population. , 2010, Asian Pacific journal of cancer prevention : APJCP.

[25]  Yiannis Koutalos,et al.  Subcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells. , 2002, Cancer research.

[26]  D. Ross,et al.  A NAD(P)H:Quinone Oxidoreductase 1 Polymorphism Is a Risk Factor for Human Colon Cancer , 2006, Cancer Epidemiology Biomarkers & Prevention.

[27]  D W Nebert,et al.  Human dioxin-inducible cytosolic NAD(P)H:menadione oxidoreductase. cDNA sequence and localization of gene to chromosome 16. , 1988, The Journal of biological chemistry.

[28]  Peter Beighton,et al.  de la Chapelle, A. , 1997 .

[29]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[30]  C. Begg,et al.  Publication bias : a problem in interpreting medical data , 1988 .

[31]  M. Watson,et al.  Role of NQO1C609T and EPHX1 gene polymorphisms in the association of smoking and alcohol with sporadic distal colorectal adenomas: results from the UKFSS Study. , 2006, Carcinogenesis.

[32]  T. Brüning,et al.  NAD(P)H quinone oxidoreductase 1 codon 609 polymorphism and its association to colorectal cancer , 2000, Archives of Toxicology.

[33]  T. Wobbes,et al.  Role of epoxide hydrolase, NAD(P)H:quinone oxidoreductase, cytochrome P450 2E1 or alcohol dehydrogenase genotypes in susceptibility to colorectal cancer. , 2006, Mutation research.

[34]  L. Berliner,et al.  NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. , 2004, Molecular pharmacology.

[35]  Nilanjan Chatterjee,et al.  CYP 1 A 1 Val 462 and NQO 1 Ser 187 polymorphisms , cigarette use , and risk for colorectal adenoma , 2005 .

[36]  Ahmedin Jemal,et al.  International Trends in Colorectal Cancer Incidence Rates , 2009, Cancer Epidemiology Biomarkers & Prevention.

[37]  J. Lotem,et al.  Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  G. Powis,et al.  Cytosolic NAD(P)H:(Quinone‐acceptor)oxidoreductase in human normal and tumor tissue: Effects of cigarette smoking and alcohol , 1990, International journal of cancer.

[39]  F. Clavel-Chapelon,et al.  Lifetime and baseline alcohol intake and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition (EPIC) , 2007, International journal of cancer.

[40]  A. Jemal,et al.  Worldwide Variations in Colorectal Cancer , 2009, CA: a cancer journal for clinicians.

[41]  M. Watson,et al.  NQO1 and mEH exon 4 (mEH4) gene polymorphisms, smoking and colorectal cancer risk. , 2002, IARC scientific publications.

[42]  H. Klamut,et al.  Transfection of COS-1 cells with DT-diaphorase cDNA: role of a base change at position 609. , 1998, British Journal of Cancer.

[43]  J. Kaprio,et al.  Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. , 2000, The New England journal of medicine.

[44]  K. Matsuo,et al.  NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese , 2002, International Journal of Clinical Oncology.

[45]  J. Barrett,et al.  Vegetable, fruit and meat consumption and potential risk modifying genes in relation to colorectal cancer , 2004, International journal of cancer.

[46]  A. Begleiter,et al.  Increased sensitivity of quinone resistant cells to mitomycin C. , 1989, Cancer letters.

[47]  W. G. Cochran.  The combination of estimates from different experiments. , 1954 .

[48]  A. Multani,et al.  Disruption of the NAD(P)H:quinone oxidoreductase 1 (NQO1) gene in mice causes myelogenous hyperplasia. , 2002, Cancer research.

[49]  Y. Kakeji,et al.  Cigarette smoking, genetic polymorphisms and colorectal cancer risk: the Fukuoka Colorectal Cancer Study , 2009, BMC Cancer.

[50]  D. Ross,et al.  NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. , 2004, Methods in enzymology.

[51]  D. Ross,et al.  Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. , 1999, Pharmacogenetics.

[52]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[53]  F. Nagengast,et al.  The Influence of Fruit and Vegetable Consumption and Genetic Variation on NAD(P)H:Quinone Oxidoreductase (NQO1) Phenotype in an Endoscopy-Based Population , 2008, Nutrition and cancer.